29 Sep 2020 - The ASX rose at the open then slumped in mid-morning trade and is now tracking 0.1% higher at noon. Shares in Seven Group Holdings (ASX:SVW) are doing well today as did Janus Henderson Group (ASX:JHG). Shares in the A2 Milk (ASX:A2M) company fell this morning. Jervois Mining (ASX:JRV) has agreed to acquire the São Miguel Paulista nickel and cobalt refinery.
29 Sep 2020 - Perseus Mining (ASX:PRU) completed the Scheme of Arrangement with Exore Resources acquiring all of their assets.
29 Sep 2020 - Atomo Diagnostics (ASX:AT1) is pleased to announce it has expanded its existing Covid-19 rapid test partnership with Access Bio LLC.
29 Sep 2020 - Corporate Travel Management (ASX:CTD) has entered into a binding agreement to acquire 100 per cent of Travel & Transport, Inc.
29 Sep 2020 - Westpac (ASX:WBC) today announced that Acting Chief Executive, Westpac Institutional Bank (WIB), Curt Zuber, will be retiring from Westpac next year.
29 Sep 2020 - Elixinol Global Limited (ASX:EXL) CEO Oliver Horn provides an updates on trading conditions across the company's key markets, its new distribution agreement in the UK with the Well Pharmacy Group, and early success with its CBD (cannabidiol ) skincare range.
29 Sep 2020 - The ASX looks set to open higher this morning as global equities rose overnight. Banks did well as they pushed the lead. In the US, Boeing nudged the Dow higher. Frankfurt closed over 3% higher. Tilt Renewables (ASX:TLT) now has all 80 turbines erected at Dundonnell Wind Farm in Western Victoria.
28 Sep 2020 - The local share market has ended the session lower after a lacklustre day of trade. The S&P ASX 200 shed 0.2 down per cent or lost 13 points to 5952. The big banks were the main drag on the market today with Westpac shedding 1.1 per cent and NAB down to 0.8 per cent.
28 Sep 2020 - Respiri Limited (ASX:RSH) CEO Marjan Mikel discusses clinical results from the company's innovative asthma management tool wheezo, a combination eHealth app and handheld device, as well as the company's strategy and outlook.
28 Sep 2020 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO James McBrayer provides an update on the company's US Phase 3 trial for Technegas, and USFDA approval process timeline, with commercial sales expected in the US for 2021.
